Oncology
Zanidatamab Expands First-Line HER2-Positive GI Care
The FDA authorized two zanidatamab-based first-line strategies for unresectable locally advanced or metastatic HER2-positive gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Rayan Salih · August 31, 2026 · 6 min